Similar results have been shown in pancreatic, metastatic and non-metastatic melanoma mouse models, where in vivo administration of IL-18 slowed tumor growth by increasing the activation and cytotoxicity of CD4+ and CD8+ T cells and NK cells [101,103,104,105], as well as their interaction with tumor cells and the robust generation of memory T cells [106]. Here, CD8A is linked to melanoma.